Source:http://linkedlifedata.com/resource/pubmed/id/15720106
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2005-2-21
|
pubmed:abstractText |
Lipodystrophy syndrome is a devastating complication of antiretroviral therapy in individuals with human immunodeficiency virus (HIV). The appearance of the associated facial lipoatrophy can be demoralizing and stigmatizing for the affected individuals to a point at which it may compromise their compliance with antiretroviral medication.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1076-0512
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
104-8
|
pubmed:meshHeading |
pubmed-meshheading:15720106-Adult,
pubmed-meshheading:15720106-Face,
pubmed-meshheading:15720106-HIV-Associated Lipodystrophy Syndrome,
pubmed-meshheading:15720106-Humans,
pubmed-meshheading:15720106-Hyaluronic Acid,
pubmed-meshheading:15720106-Injections, Subcutaneous,
pubmed-meshheading:15720106-Male
|
pubmed:year |
2005
|
pubmed:articleTitle |
Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy.
|
pubmed:affiliation |
Department of Dermatology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario.
|
pubmed:publicationType |
Journal Article,
Case Reports
|